Text Size

Study of Bile Acids in Patients With Peroxisomal Disorders

The recruitment status of this study is unknown because the information has not been verified recently.
Verified November 2000 by FDA Office of Orphan Products Development.
Recruitment status was  Not yet recruiting
Sponsor:
Collaborator:
Children's Hospital Medical Center, Cincinnati
Information provided by:
FDA Office of Orphan Products Development
ClinicalTrials.gov Identifier:
NCT00004442
First received: October 18, 1999
Last updated: June 23, 2005
Last verified: November 2000
History of Changes
  Purpose

OBJECTIVES: I. Determine the effectiveness of oral bile acid therapy with cholic acid, chenodeoxycholic acid, and ursodeoxycholic acid in patients with peroxisomal disorders involving impaired primary bile acid synthesis.

II. Determine whether suppression of synthesis of atypical bile acids and enrichment of bile acid pool with this regimen is effective in treating this patient population and improving quality of life.


Condition Intervention
Infantile Refsum's Disease
Zellweger Syndrome
Bifunctional Enzyme Deficiency
Adrenoleukodystrophy
 Drug: chenodeoxycholic acid
Drug: cholic acid
Drug: ursodiol

Study Type: Interventional
Study Design: Primary Purpose: Treatment

Resource links provided by NLM:

U.S. FDA Resources

Further study details as provided by FDA Office of Orphan Products Development:

Estimated Enrollment: 25
Detailed Description:

PROTOCOL OUTLINE: Patients receive oral cholic acid and oral chenodeoxycholic acid on day 1. On day 4, patients receive oral cholic and ursodeoxycholic acids. Patients are assessed at 3 and 6 months for liver function response, neurologic status, and nutritional status.

Patients receive treatment until disease progression or unacceptable toxic effects are observed.

  Eligibility

Ages Eligible for Study:   up to 5 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Biochemically proven peroxisomal disorder, including:

  • Zellweger syndrome
  • Pseudo-Zellweger syndrome
  • Neonatal adrenoleukodystrophy
  • Bifunctional enzyme deficiency
  • Infantile Refsum's disease
  Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT00004442

Contacts
Contact: Kenneth Setchell 513-636-4548

Sponsors and Collaborators
FDA Office of Orphan Products Development
Children's Hospital Medical Center, Cincinnati
Investigators
Study Chair: Kenneth Setchell Children's Hospital Medical Center, Cincinnati
  More Information

No publications provided

ClinicalTrials.gov Identifier: NCT00004442     History of Changes
Other Study ID Numbers: 199/13442, CHMC-C-FDR000995
Study First Received: October 18, 1999
Last Updated: June 23, 2005
Health Authority: United States: Federal Government

Keywords provided by FDA Office of Orphan Products Development:
Zellweger syndrome
adrenoleukodystrophy
bifunctional enzyme deficiency
inborn errors of metabolism
infantile Refsum's disease
 peroxisomal disorders
pseudo-Zellweger syndrome
rare disease
sphingolipidoses

Additional relevant MeSH terms:
Adrenoleukodystrophy
Refsum Disease
Zellweger Syndrome
Refsum Disease, Infantile
Peroxisomal Disorders
Brain Diseases, Metabolic, Inborn
Brain Diseases, Metabolic
Brain Diseases
Central Nervous System Diseases
Nervous System Diseases
Hereditary Sensory and Motor Neuropathy
Nervous System Malformations
Heredodegenerative Disorders, Nervous System
Neurodegenerative Diseases
Polyneuropathies
 Peripheral Nervous System Diseases
Neuromuscular Diseases
Congenital Abnormalities
Genetic Diseases, Inborn
Metabolism, Inborn Errors
Metabolic Diseases
Liver Diseases
Digestive System Diseases
Kidney Diseases
Urologic Diseases
Abnormalities, Multiple
Hereditary Central Nervous System Demyelinating Diseases
Leukoencephalopathies
Demyelinating Diseases
Mental Retardation, X-Linked

ClinicalTrials.gov processed this record on June 18, 2013